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This editorial refers to ‘Protective effects of Angiopoietin-Like 4 on cerebrovascular and functional 
damages in ischemic stroke’, by Claire Bouleti et al., manuscript number D-12-02901R2 
Stroke is a global cause of morbidity and mortality, ranking fourth among all causes of death1. 
Although considerable progress has been made in developing effective tools for acute stroke 
treatment, at present, the only drug approved is recombinant tissue plasminogen activator (rt-PA); 
thus, new strategies for its effective prevention and treatment are essential. Following 
ischemia/reperfusion, the blood-brain barrier (BBB) becomes more permeable and, in doing so, it 
promotes an increased infiltration of pro-inflammatory cells resulting in the so called “reperfusion 
injury” 2. Given its key role in mediating ischemia/reperfusion-related neuronal damage, the BBB is a 
central target for the development of novel therapeutical strategies. 
Bouleti and colleagues provided an elegant study reporting a new target improving stroke outcome 
in mice. Their study shows that Angiopoietin-like 4 (ANGPTL4) modulates endothelial permeability 
following ischemia/reperfusion and thus represents a potential new therapeutical target for the 
treatment of stroke.  
ANGPTL4, first discovered in 2000, was originally classified as an adipokine playing roles in lipid 
metabolism3. Over the last decade, ANGPTL4 was recognized to play additional roles as also in 
tumorigenesis, angiogenesis and redox regulation3. Bouleti and colleagues investigated the role of 
ANGPTL4 in stroke by using a transient focal cerebral ischemia murine model, where the middle 
cerebral artery was occluded for 1 hour, followed by 24 hours of reperfusion. Indeed, they could 
show that recombinant human ANGPTL4 (rhANGPTL4) treatment prior to the ischemic episode 
strongly reduced stroke size and consequent neurological deficit. To provide additional supporting 
evidence for the protective effects of ANGPTL4, Bouleti et al. analyzed stroke outcome in ANGPTL4 
knockout mice undergoing ischemic stroke. Moreover, to translate their findings into a more 
clinically relevant experimental setup, the authors treated mice with rhANGPTL4 upon reperfusion, 1 
hour after the ischemic event. Both in ANGPTL4 knockout mice as well as in the post-ischemic 
rhANGPTL4-treated mice, the authors could confirm the protective effects of ANGPTL4 on stroke. 
Finally, to test the responsiveness of ANGPTL4 to stroke also in humans, Bouleti et al. stained brain 
samples of patients who had previously died from ischemic stroke and demonstrated an increased 
expression of ANGPTL4.  
Given the key role of vascular integrity in determining stroke outcome2, Bouleti and colleagues 
focused on analyzing endothelial networks to characterize the protective effects of rhANGPTL4 
treatment on stroke outcome. They demonstrated an improved endothelial network after 
ischemia/reperfusion brain injury in the rhANGPTL4-treated mice as compared to controls, 
indicating a preservation of the vasculature during stroke. Cerebral endothelial cells build the initial 
barrier of the blood-brain barrier (BBB) separating blood components from brain cells, and are 
connected by tight and adherens junction proteins4. A disruption of these cell-cell contacts leads to 
vascular leakage, oedema formation and brain damage. In the present work, integrity of tight and 
adherens junctions was assessed by characterizing Claudin-5 and VE-cadherin, two main junction 
proteins4. The authors showed an increase in Claudin-5 and VE-cadherin-positive areas after 
ischemia/reperfusion injury in the rhANGPTL4-treated mice compared to the control mice, indicating 
an effect of ANGPTL4 on preserving the integrity of tight and adherens junctions in stroke.  
Acutely, vascular endothelial growth factor (VEGF) is a potent mediator of vascular permeability and 
its antagonism has been shown to reduce ischemia/reperfusion related brain oedema and injury5. 
Given the important role of VEGF as a mediator of acute vascular leakage following ischemia6 
(Fig.1), Bouleti et al. tested the possibility that rhANGPTL4 treatment may act by disrupting VEGF 
receptor 2 (VEGFR2) signalling. Indeed, they showed that ANGPTL4 maintains vascular integrity 
via inhibition of VEGF-induced, VEGFR2-mediated, disruption of VE-Cadherin and Claudin-5; a 
process in turn depending on Src phosphorylation and phosphoinositid-3 kinase (PI3K)/Akt 
activation (Fig.1).  
Transmigration of circulating cells from the vasculature into the brain is a key step in tissue damage 
following ischemia/reperfusion injury. This event is promoted, in part, by an up regulation of 
endothelial adhesion molecules. Bouleti and colleagues demonstrated that rhANGPTL4 treatment 
reduces intercellular adhesion molecule-1 (ICAM-1) expression in the ipsilateral hemisphere of 
rhANGPTL4-treated mice as compared to controls, indicating that ANGPTL4 may also interfere with 
inflammatory responses following ischemia/reperfusion.   
In the clinical setting, rt-PA was first approved by FDA in 2006 for the treatment of ischemic stroke 
within three hours from symptom onset, after the publications of NINDS trial7, in which a 12 percent 
absolute (32 percent relative) increase in the number of patients with minimal or no disability was 
achieved in the rt-PA group compared to placebo. However, access to rt-PA is limited by numerous 
contraindications, which make this treatment available only for a minority of patients. In addition, rt-
PA treatment is burdened by a major complication, ie. hemorrhagic evolution of the ischemic lesion, 
which is one of principal reasons given by many emergency room physicians and neurologists for 
their avoidance of use of rt-PA therapy. 
The Authors demonstrate that administration of ANGPTL4 in an ischemic stroke model decreases 
infarct size and improves neurological function by maintaining vascular integrity through prevention 
of BBB breakdown.  
From a clinical perspective, these data are very interesting, as we do know that BBB breakdown is 
involved both in ischemic and hemorrhagic stroke, as well as in the hemorrhagic transformation of 
ischemic stroke, either spontaneously or after rt-PA administration. 
However, even if numerous neuroprotective agents have been already shown to be effective in 
ameliorating outcome in experimental models of stroke, up to now, clinical neurologists are faced 
with a long list of failures in the translation to the clinical setting.  To address this issue, the Stroke 
Therapy Academic Industry Roundtable (STAIR) published in 1999 the recommendations to 
improve the quality of preclinical studies of acute stroke therapies8, further updated in 20099.  These 
guidelines include, first of all, methodological standards, such as random allocation, allocation 
concealment, sample size calculation, inclusion and exclusion criteria, randomization, reporting of 
animals excluded from analysis, and blinded assessment of outcome, as well as reporting of 
potential conflicts of interest and study funding. In addition, the authors underline the intrinsic 
limitations of animal stroke models, the most relevant being that ischemia is experimentally induced 
in otherwise healthy animals, whereas human stroke occurs in the context of different risks factors 
and concomitant medications. Finally, accumulating data suggest that many of the neuroprotective 
targets tested in preclinical models may have a negative effect on the recovery process. Thus, any 
acute therapy must consider if the desired target plays a role in the subsequent process of recovery. 
Accordingly, multiple end-points, such as histological end-points, biological markers, imaging data, 
behavioral and functional outcomes, should be carefully identified and tested at the appropriate 
time-points. In line with these consideration, many of the animal models demonstrated optimal 
benefit at a timeframe that was not practical for clinical stroke intervention such as either pre-
treatment or within 90 minutes of the infarction. Because the onset-to-needle time in the real world 
is relatively long, the time window in animal experiments should be defined accordingly. 
Bouleti and colleagues show very convincingly and in detail the vasculoprotective properties of 
ANGPTL4 in ischemic stroke. In particular, the post-ischemic treatment with rhANGPTL4 provides 
clinical relevance and sets the basis for follow up investigations. However, there are also some 
limitations to this work, which should be mentioned. First of all, all analysis concerning stroke size, 
neurological deficit, as well as mechanisms are performed at short time points and no data are 
provided to confirm the protective effects of rhANGPTL4 treatment beyond 24 hours. Given the 
known biphasic nature of some of the molecular signals activated during stroke, the role of 
ANGPTL4 on vascular integrity and stroke outcome should also be studied long-term to fully 
elucidate its therapeutical potential. Secondly, most in vitro experiments are conducted on human 
endothelial cells of venous or dermal origin while we feel that mechanistic studies should also be 
confirmed on human endothelial cells originating from cerebral arteries to exclude possible cell type-
specific effects. 
Recently, stroke research reached beyond the role of the BBB; indeed a number of other 
approaches have also been considered. Free radicals are important mediators of BBB damage 
following ischemia thus different strategies to prevent the surge of ROS have been successfully 
studied10, 11. Additionally, much focus has also been put on studying the therapeutical potential of 
stem cell transplantation in stroke patients. Although its effectiveness in stroke animal models12 as 
well as its clinical safety and feasibility were demonstrated13, the clinical efficacy of stem cell therapy 
still has to be improved14 so as to become a concrete therapeutical alternative and at present this 
scenario seems still far.  
We do hope that, if the results obtained by Bouleti and colleagues will be confirmed by further 
experiments adhering to the suggested recommendations, any clinical trial implemented will not run 
into previously observed trivialities. The world outside desperately needs effective new therapies to 
combat against stroke, which causes every year millions of disabled, and is likely to cause even 
more with the aging population. 
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